Recently, we discovered that IRF3, a central transcription factor in antiviral innate immunity, acts as an agonist of YAP-TEAD in gastric cancer and that pharmacological inhibition of IRF3 by amlexanox suppresses YAP-driven gastric tumor growth6. The gene discussed is IRF3; the disease is gastric neoplasm.